of Helsinki and Uusimaa between January 1, 2014, and July 1, 2015, were identified. The principal investigator (N.K.) reviewed all medical files for inclusion into the study: patients ≥ 18 years of age with HS diagnosed ≥ 6 months before study initiation with the ability to provide informed consent. All three diagnostic criteria for HS had to be met: presence of typical lesions, location of lesions in typical areas, and an evolving disease course with relapses and chronicity. Of 69 identified patients, 18 did not meet the eligibility criteria. Of 51 eligible patients, 11 could not be contacted due to insufficient contact information and 1 died. Of the remaining 39 patients, 4 declined to participate and 6 did not participate for the following reasons: currently symptomless, scheduled for surgery, pregnancy, and other illness. Altogether, 29 patients provided consent to participate in the study. Of these, 1 died before the study visit, 1 had Down's syndrome and was not able to answer the questionnaires herself, and 1 did not show up for the study visit. In total, 26 patients were included in the study. The study was divided into 3 sections: chart review, patient questionnaires, and study visit to the physician. To protect patient confidentiality, all personally identifiable information was de-identified in all 3 sections.
Chart Review and Study Visit to the Physician
Medical charts of eligible patients were screened. Data were collected on demographics, social and economic status, personal and familial history of HS, lifestyle, comorbidities, clinical presentation and severity of HS, and burden on the healthcare system (e.g., HS-related surgeries).
During the study visit, the principal investigator (N.K.) assessed current disease status (i.e., disease severity according to Hurley stage and clinical presentation) and collected information on treatment patterns and HS-related sick time over the past year. Patients were also asked to rank 10 HS-related symptoms according to the impact on their everyday life. The most bothersome symptom was scored 1 and the least bothersome symptom was scored 10. The DLQI is the most frequently used instrument in randomized controlled trials in dermatology [4] . It is a simple, validated questionnaire that consists of 10 questions. Each question has 4 possible answers for a maximum of 3 points and a total maximum score of 30. Higher score indicates more severely affected QoL. A total score of 0-1 indicates no effect on QoL, 2-5 indicates a small effect, 6-10 indicates a moderate effect, 11-20 indicates a very large effect, and 21-30 indicates an extremely large effect [4, 5] .
Questionnaires
The BDI-21 is one of the most widely used instruments for measuring depression [6] . We consulted a psychiatrist, who veri- at diagnosis, duration of the disease, level of education, number of HS-affected locations, Hurley staging, comorbidities, and total DLQI and BDI-21 scores were analyzed using the Spearman rank correlation coefficient. A stepwise regression analysis estimated how gender, smoking (pack-years), alcohol consumption (grams per week), body mass index, overall number of comorbidities, and severity of the disease (Hurley staging, number of affected locations) affected the variance in the BDI-21 and DLQI scores. The statistical regression threshold was set at p = 0.15 for inclusion into the model. p < 0.05 (2-sided) was considered statistically significant. 
Results

Demographic Data
Of 26 patients with HS, 10 were men (38.5%) and 16 were women (61.5%); mean age of patients was 44.2 ± 15.5 years (range, 23-72 years). Totally, 96.2% (25/26) were white; 1 was of African descent. Men were slightly older (49.4 ± 12.9 years; range, 29-66 years) than women (40.9 ± 14.9 years; range, 23-72 years). Mean age at HS diagnosis was 40.5 ± 15.0 years (range, 18-70 years); however, the mean age at onset of HS was 26.8 ± 14.9 years (range, 8-66 years). Mean average disease duration was 18.4 ± 10.2 years ( Table 1 ). There were no statistically significant differences between genders for age, age at onset, age at diagnosis, or disease duration. Family history of HS was reported in less than a third of the cases (30.4%; 7/23), of which 6 cases (85.7%) were in first-degree relatives (parents or siblings, including 1 twin sister). In one case, a second-degree relative was affected (aunt). More than half (57.5%) had a high school or higher educational degree and 58.3% had an annual income between EUR 25,000 and 59,999. Totally, 16 patients (61.5%) were employed.
Clinical Presentation of HS
Medical file information on clinical presentation and disease severity was limited. At the time of interview, 13 patients (50.0%) had Hurley stage I, 11 (42.3%) had Hurley stage II, and 2 (7.7%) had Hurley stage III ( Table 1 ) . The body regions most commonly affected were the inguinal (76.9%) and axillary (61.5%) regions, as well as the buttocks (11.5%). Mean number of affected areas was 2.04 ± 1.58 (range, 1-4). In men, the inner thigh/groin area was affected in 80% of the cases, followed by the armpits (60%) and buttocks (40%). Among women, the inner thigh/groin area was affected in 75.0% of cases, followed by the armpits (62.5%), buttocks (25.0%), and breasts (18.8%). No significant differences were observed between men and women (χ 2 test).
Lifestyle and Comorbidities
All men were present or past smokers, while 37.5% (6/16) of women had never smoked. Men smoked more than women (Mann-Whitney U test, p = 0.006). Alcohol consumption was more frequent among men (90.0% of men [9/10] vs. 62.5% of women [10/16] ), men also con- 
Pain, Quality of Life, and Depression
Patients were asked to rank a list of 10 HS-related symptoms according to the impact on their everyday life. Results are presented as means of the symptom scores as rated by each patient ( Fig. 2 ) . Pain was ranked as the most bothersome HS-related symptom (mean score, 3.27).
Mean DLQI score was 8.31 ± 7.39 (3.00 ± 3.77 for men and 11.63 ± 7.22 for women). The difference was statistically significant between men and women, with women having higher scores (Mann-Whitney U test, p = 0.002). Nine patients (34.6%), all women, reported a very large to extremely large effect on their daily life (DLQI >10). The items most affected were skin symptoms and embarrassment (38.5%), problems with clothing (36.0%), and impaired sexuality (26.6%; Fig. 3 a) . Women had higher scores than men for every DLQI item. The most notable difference between men and women was observed for the embarrassment item ( p < 0.001). In addition, scores for clothing ( p = 0.010), problems with partners, relatives, or close friends ( p = 0.004), and sexuality ( p = 0.007) were statistically significantly higher in women than men ( Fig. 3 b) . Skin symptoms ( p = 0.052) and social/leisure activities ( p = 0.070) were affected, but without significant inter-gender differences. Higher Hurley stage at visit ( p = 0.001), female gender ( p = 0.018), and higher BDI-21 total score ( p = 0.022) were variables that significantly affected the total DLQI score in stepwise regression analysis.
Mean total BDI-21 score was 10.69 ± 10.13. Women had higher scores than men (mean, 15.00 ± 10.32 vs. 3.80 ± 4.66; Mann-Whitney U test, p = 0.002). According to BDI-21 severity grading, 10 patients (38.5%), of which 9 were women, reported depression symptoms (BDI-21 >12); mild, moderate, and severe depression were reported in 6, 2, and 2 patients, respectively. Four patients reported depression during the interview. BDI-21 scores did not correlate with the age of the patient, the age at diagnosis, HS duration, the number of affected areas, Hurley staging at the time of interview ( r = -0.351; p = 0.079), the number of comorbidities, or any comorbidities except for depression ( r = 0.450; p = 0.021). Total BDI-21 and DLQI scores correlated ( r = 0.509; p = 0.008). Female gender ( p = 0.004) was the only significant variable that significantly affected the total BDI-21 score using stepwise regression analysis.
Diagnostic Delay
Mean delay of HS diagnosis (i.e., start of symptoms to diagnosis of disease) was 13.7 ± 10.0 years. Diagnoses received prior to the HS diagnosis included abscesses (30.8%; 8/26), folliculitis/furunculosis (19.2%; 5/26), and acne (11.5%; 3/26). However, no clear diagnosis existed for the majority of patients (53.8%; 14/26) before receiving an HS diagnosis.
Impact on Workability
Results from the WPAI-SHP questionnaire showed that, of those employed ( n = 16; 61.5%), 2 (12.5%) missed a mean of 28.75 h from work during the past 7 days because of problems associated with HS. The rest of the employed patients ( n = 14) reported no absence from work during the past 7 days. The results from the patient interview showed that, over the past year, the mean number of HS-related sick days was 14.2 days ( n = 22). The number of sick days ranged from 0 to 120 days, with 50% of patients using no sick days. Of those reporting sick days, 81% estimated that their sick time ranged from 2 to 15 days. Two patients, both with Hurley stage III disease, reported 112 and 120 days of HS-related sick leave, respectively.
Treatment
At the time of the interview, 42.3% of the patients (11/26) were managed at the university hospital, 30.8% (8/26) at their own healthcare center, 3.8% (1/26) at a private practice, and 3.8% (1/26) at occupational healthcare. Five patients (19.2%) were currently not seeking care for their condition. All patients had experienced local treatment (antiseptics, local antibiotics) or oral antibiotics. Thirteen patients (50.0%) were either using or had used oral retinoids, either isotretinoin (10/26; 38.5%) or acitretin (4/26; 15.4%); 1 patient had tried both. Only 1 patient had received biologic treatment in the past (adalimumab for the treatment of Crohn's disease). Oral pain medication, mainly nonsteroidal anti-inflammatory drugs (71%), had been used by 26.9% of patients (7/26). Totally, 69.2% had undergone incision and drainage; 50.0% (13/26) already before their HS diagnosis. 23.1% (6/26) still required these procedures occasionally. 19.2% had undergone local excision and 11.5% wide excision.
Discussion
This is the first published report on the clinical characteristics and burden of disease in Finnish patients suffering from HS. Of note, a Scandinavian HS registry was recently established [8] , but to our knowledge, it does not include any Finnish patients. We performed a cross-sectional pilot study on 26 patients in a single hospital district. Our findings are in line with current literature; a majority of patients were women and most were overweight or obese as well as smokers [9] [10] [11] . Family history was reported in approximately a third of the cases [12] . Surprisingly, we found an elevated mean delay of diagnosis of 13.7 years. This delay is longer than previously reported [11] [12] [13] and may have been caused by a delay in Itchy, sore, painful, or stinging skin
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Problems with treatments consulting a physician, the consulted physician not making the correct diagnosis, or both. The patient interviews indicated that the diagnostic delay was primarily caused by the healthcare provider. In the Finnish healthcare system, only the general practitioner in a local health center can decide on referral. This may play a significant role in diagnostic delay, especially in HS, where symptoms occur in cycles. The education of general practitioners in healthcare centers, from which the majority of referrals came, is crucial for timely referral to a specialist enabling accurate diagnosis.
Pain is reportedly an important aspect of HS. In the literature, HS-related pain has been described as "hot, burning, pressure, stretching, sharp, and splitting" [14] . In our study, pain was reported as the most disabling and bothersome symptom. The mechanism behind HS-related pain is still unknown and warrants further investigation [15, 16] .
The impact of HS on QoL is well documented [17, 18] . In our cohort, the mean DLQI score was 8.3, which is in line with results from other cohorts. Interestingly, in our study, women were clearly more affected than men in all aspects of the DLQI, especially embarrassment, clothing, sexuality, and social relationships. To our knowledge, this is the first report showing statistically significant differences in DLQI scores between men and women with HS. We report similar results regarding depression; according to BDI-21 scores, mainly women (90.0%) reported symptoms of depression. Four patients (15.4%) disclosed moderate to severe symptoms. The two patients with the highest BDI-21 total scores had received a diagnosis of depression before the diagnosis of HS. Due to the small sample size and the long diagnostic delay of HS reported in our cohort, it is difficult to draw a definitive conclusion on the relationship between depression and HS.
We assessed the impact of HS on workability in terms of sick days over the past year. Most patients tended not to take sick days because of HS. Only the most severely affected patients reported long sick leaves. It seems that Finnish patients, at least in our cohort, are quite resilient regarding their disease.
Our study has some limitations. It was a descriptive study without any control group. In addition, we cannot rule out the fact that the sample size ( n = 26) may have affected our results. Nevertheless, our study showed similar results to other European and North American studies with regards to demographics, clinical presentation, comorbidities, and impact on QoL. Despite the limitations, our results are not based on a chart review only, but are supplemented with data from patient interviews, physical examinations, and patient questionnaires. The patient interview allowed the patient to provide his or her own valuable insight into the burden of HS on the QoL.
Even though our results largely confirm those of others, we report novel findings on diagnostic delay and inter-gender-specific differences in QoL. The surprisingly long mean delay in diagnosis highlights the need for education of general practitioners in Finnish healthcare centers, as they may enable early diagnosis by timely referral to dermatologists. The QoL of patients suffering from HS, as measured by DLQI, is clearly impaired. In this pilot study, both DLQI and BDI-21 scores suggest that there is a clear difference between men and women, with women being more impacted by the disease. In the near future, we aim at extending this study to a nationwide scale.
